TMCnet News
Rubius Therapeutics to Participate in Jefferies London Healthcare ConferenceCAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced today that Pablo J. Cagnoni, M.D., chief executive officer, will present at Jefferies London Healthcare Conference Wednesday, November 20, 2019, at 10:00 a.m. GMT / 5:00 a.m. EST. A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event. About Rubius Therapeutics Contact: Lori Melançon Vice President, Corporate Communications and Investor Relations +1 (617) 949-5296 [email protected] Media Contact: |